User healthcare professionals working in one of the establishments mentioned in 4° of Article R. 5222-3 or in a blood transfusion establishment immediately report to the local reactovigilance correspondent any incidents or risks of incidents involving an in vitro diagnostic medical device of which they are aware. In an emergency, the healthcare professional will forward the report directly to the Director General of the Agence nationale de sécurité du médicament et des produits de santé.